


CLAIMS

What is claimed is:

- An isolated Akt3 inhibitor selected from the group consisting of an antisense oligonucleotide, a ribozyme, a protein, a polypeptide, an antibody, and a small molecule.
- 2. The isolated Akt3 inhibitor of claim 1 wherein said Akt3 inhibitor is an antisense molecule.
- 3. The isolated Akt3 inhibitor of claim 2 wherein said antisense molecule or the complement thereof comprises at least 10 consecutive nucleic acids of the sequence of SEQ ID NO:1.
- 4. The isolated Akt3 inhibitor of claim 3 wherein said antisense molecule or the complement thereof hybridizes under high stringency conditions to the sequence of SEQ ID NO:1.
- 5. The isolated Akt3 inhibitor of claim 2 wherein said antisense molecule comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:2-6 and 12-19.
- 6. The isolated Akt3 inhibitor of claim 1 wherein said Akt3 inhibitor is a ribozyme.



A composition, comprising a therapeutically effective amount of a Akt3 inhibitor in a pharmaceutically acceptable carrier.

selected from the group consisting of an antibody and an antibody fragment.

- 9. The composition of claim 8, comprising two or more Akt3 inhibitors.
- 10. The composition of claim 8 wherein said Akt3 inhibitor is an antisense molecule.
- 11. The composition of claim 10 wherein said antisense molecule or the complement thereof comprises at least 10 consecutive nucleic acids of the sequence of SEQ ID NO:1.
- 12. The composition of claim 10 wherein said antisense molecule comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:2-6 and 12-19.
- 13. A method of decreasing the expression of Akt3 in a mammalian cell, comprising administering to said cell an Akt3 inhibitor of claim 1.
- 14. The method of claim 13 wherein said Akt3 inhibitor is an antisense molecule.



- 15. A method of treating neoplastic disease, comprising administering to a mammalian cell an Akt3 inhibitor of claim 1 such that said neoplastic disease is reduced in severity.
- 16. An antisense compound of 8 to 35 nucleotides in length targeted to a nucleic acid molecule encoding human Akt3, wherein the antisense compound inhibits the expression of human Akt3.
- An isolated polynucleotide with a sequence comprising a transcriptional initiation region and a sequence encoding an antisense oligonucleotide at least 8 nucleotides or nucleotide analogues and not longer than 35 nucleotides in length comprising a sequence selected from the group consisting of SEQ ID NOS:2-6 and 12-19.
- 18. A recombinant vector comprising polynucleotide having a DNA with a sequence of claim 17.

